Zimmer Biomet Holdings (ZBH) Tops Q3 EPS by 2c; Bumps FY Outlook Higher

Zimmer Biomet Holdings (NYSE: ZBH) reported Q3 EPS of $1.58, $0.02 better than the analyst estimate of $1.56. Revenue for the quarter came in at $1.67 billion versus the consensus estimate of $1.64 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2022 EPS of $6.80-$6.90, versus prior of $6.70-6.90 and the consensus of $6.79. Sees sales 0-1%, versus (1%)-1%.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Medtronic (MDT) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY27 EPS Guidance
• GitLab Inc (GTLB) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY Guidance